ARCT News and Press, Arcturus Therapeutics Ltd. From 11/08/21

Arcturus Therapeutics (NASDAQ:ARCT): Q3 GAAP EPS of -$2.05 misses by $0.72. Revenue of $2.44M (+6.1% Y/Y) misses by $16.76M. Shares +2%. Press Release For further details see: Arcturus Therapeutics EPS misses by $0.72, misses on revenue

Phase 1/2/3a and 3b study of ARCT-154 COVID-19 vaccine candidate completed enrollment with over 17,000 participants Initiated ~2,000 participant ARCT-154 Phase 3c sub-study to compare immunogenicity noninferiority to AstraZeneca COVID-19 vaccine; enrollment to be completed...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

- Phase 3b dosing of ARCT-154 initiated; study designed to enroll approximately 20,000 participants - Initiation of Phase 3b study follows review of safety data from initial 1,000 Phase 1/2/3a participants - ARCT-154 remains on track for Emergency Use Authorization (EU...

Gainers: Voyager Therapeutics (NASDAQ:VYGR) +57%, Acer Therapeutics (NASDAQ:ACER) +9%, Molecular Partners (NASDAQ:MOLN) +10%, Rafael (NYSE:RFL) +6%, Arcturus Therapeutics (NASDAQ:ARCT) +7%. Losers: Ginkgo Bioworks (NYSE:DNA) -21%, OpGen (...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Phase 1 (100 participants): both doses completed Phase 2 (300 participants) has initiated Phase 3a (600 participants) on track to initiate by end of September Phase 3b (20,000 participants) dosing planned for first week of October ARCT-154 remains on tr...

The company has a specific opportunity to be a vaccine supplier within Asia and to the world. Re-instated trials are proceeding after disappointment earlier in the year. As a well-capitalised company, there should be no shareholder risk dilution for a couple of years. Company ...